Insulin resistance in patients with rheumatoid arthritis: effect of anti-TNFalpha therapy

A Rosenvinge, R Krogh-Madsen, B Baslund, B K Pedersen


OBJECTIVES: We undertook this study to test the hypotheses that patients with active rheumatoid arthritis (RA) are insulin resistant and that anti-tumour necrosis factor-alpha (TNFalpha) therapy improves not only the clinical state of these patients but also their glucose metabolism.

METHODS: Nine RA patients with active disease and nine healthy subjects, matched for sex, age, and body mass index (BMI), underwent a hyperinsulinaemic euglycaemic clamp. The RA patients received anti-TNFalpha therapy with Humira(adalimumab) and had the insulin clamp re-evaluated after 8 weeks of treatment.

RESULTS: Patients with RA had marked insulin resistance (glucose infusion rate (GIR) area under the curve (AUC) was 499+/-55 mg/kg in the RA group compared to 710+/-77 mg/kg in the control group; p<0.05). However, insulin sensitivity did not differ before and after 8 weeks of adalimumab therapy. The RA patients demonstrated a reduction in C-reactive protein (CRP) and interleukin-6 (IL-6) levels after the therapy as compared to pretreatment values, but there was no concomitant effect on plasma levels of TNFalpha.

CONCLUSION: RA patients with active disease showed marked insulin resistance that was not influenced by anti-TNFalpha therapy despite a reduction in systemic inflammation during the treatment.

TidsskriftScandinavian Journal of Rheumatology
Udgave nummer2
Sider (fra-til)91-6
Antal sider6
StatusUdgivet - 2007
Udgivet eksterntJa


Dyk ned i forskningsemnerne om 'Insulin resistance in patients with rheumatoid arthritis: effect of anti-TNFalpha therapy'. Sammen danner de et unikt fingeraftryk.